echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > HengRui sets up a new company to formally enter the field of antiviral drugs

    HengRui sets up a new company to formally enter the field of antiviral drugs

    • Last Update: 2020-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "
    Pharmaceutical Network Corporate News: July 6, Hengrui announced that the wholly-owned subsidiary Shanghai Hengrui intends to jointly fund the establishment of Ruilidi (Shanghai) Biopharmaceutical Co., Ltdwith the associated natural person Sun LifuAmong them, Shanghai Hengrui invested 60 million yuan, accounting for 60% of the shares, Sun Yiyang invested 40 million yuan, accounting for 40% of the sharesit is understood that Reedi's business scope includes technology development, technical consulting, technical services, technology transfer in the field of biomedicine, and will also be responsible for the research and development, production, sales and related import and export business of antiviral therapyit is understood that Hengrui Pharmaceutical's product pipeline has been covering anti-tumor drugs, surgical anesthesia drugs, special infusions, contrast agents, cardiovascular drugs and other fields, not involved in antiviral drugsIn this regard, HengRui said that antiviral drugs are the company's new areas, this transaction is conducive to the company's rich product line, is an important part of the company's development strategy, to improve product structure, improve product market competitiveness has a long-term impactwell known, antivirals and anti-tumors are in two directionsAt present, more common viral infections include AIDS, viral hepatitis, influenza, herpes and so ondata show that the antiviral drug market peaked at $61.4 billion in recent years in 2016 and has since declined for two years, but the global antiviral market size in 2018 is still $55.09 billionAnti-HIV infection and anti-hepatitis virus are two important areas in the antiviral drug marketAmong them, the scale of anti-HIV drug market is increasing year by year, in 2018 has exceeded 30 billion U.Sdollars, and there is a trend of continued growthTherefore, the global research antiviral drugs also basically around hepatitis B and HIV, the two accounted for 34% and 28%, respectively, the third is influenza, accounting for 8%at present, there are 97 drugs listed worldwide and used in antiviral treatment since 1995, mainly including chemical drugs, biologics, cell therapy drugs and Chinese herbal medicine (including plant extracts ) To HIV and hepatitis treatment drugs mainly, compound drugs sales are higher, including Gilead's research and development of products One-third of the antiviral drugs on the market are listed in China, and 38 are chemical drugs However, it is worth noting that most drugs are on the market earlier, the number of innovative drugs in recent years is small, and because THE HIV and hepatitis virus treatment of common drug patents have not yet expired, a large number of enterprises can only focus on imitation of ribavirin, Asilovir, more ciillove and other broad-spectrum antiviral drugs in fact, in recent years, in the global "tumor fever" background, most of the world's pharmaceutical companies have focused their research and development on anti-tumor drugs But the year-to-date outbreak has dealt a heavy blow, and the short board of antiviral drug development has been completely exposed The recurrence of the outbreak has also led more and more pharmaceutical companies to focus on the field of antiviral drugs to treat new infectious diseases In addition to Heng Rui's involvement in the field of antivirals, people like Kingsley Bio said in an interview in February that they had launched research into infectious diseases In addition, there are a small number of anti-viral drugs in the field of anti-viral drugs have a layout of the old pharmaceutical companies, such as Zhengda Sunny, East Sunshine Medicine, Clarion Pharmaceuticals, frontier biology and so on are still in this area of sustained strength in general, this outbreak has made us acutely aware of the importance of antiviral drug research and development, and more and more pharmaceutical companies are beginning to move towards this area In the future, pharmaceutical companies need long-term solid antiviral drug research and development, in order to do a good job at any time to respond to the outbreak of prevention and control, benefit more patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.